All IndicationsOncologyApprovedPhase 3Phase 3Phase 3Phase 3Phase 1
🎗️
relapsed/refractory multiple myeloma
5
Companies
7
Drug Programs
4
Phase 3
0
Upcoming PDUFAs
Competitors
BMY
Bristol Myers Squibb
iberdomide
ABBV
AbbVie
etentamig
ABBV
AbbVie
Etentamig
CBDY
Celgene
Teclistamab
JNJ
Johnson & Johnson
TECVAYLI
CBDY
CellBody Therapeutics
Cevostamab
ACTI
Arcus Therapeutics
CAR T-Cell Therapy
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| BMY Bristol Myers Squibb | iberdomide | Approved | — | — | — |
| ABBV AbbVie | etentamig | Phase 3 | — | — | — |
| ABBV AbbVie | Etentamig | Phase 3 | — | — | — |
| CBDY Celgene | Teclistamab | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | TECVAYLI | Phase 3 | — | — | — |
| CBDY CellBody Therapeutics | Cevostamab | Phase 1 | — | — | — |
| ACTI Arcus Therapeutics | CAR T-Cell Therapy | — | — | — | — |
Development Stage Distribution
Unknown
1
Approved
1
Phase 3
4
Phase 1
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.